An analysis of the attrition of drug candidates from four major pharmaceutical companies

Michael J. Waring(AstraZeneca (United Kingdom)), John Arrowsmith(Thomson Reuters (United Kingdom)), Andrew R. Leach(GlaxoSmithKline (United Kingdom)), Paul D. Leeson, Sam Mandrell(Thomson Reuters (United Kingdom)), Robert M. Owen, Garry Pairaudeau(AstraZeneca (United Kingdom)), William D. Pennie, Stephen D. Pickett(GlaxoSmithKline (United Kingdom)), Ji‐Bo Wang(Eli Lilly (United States)), Owen B. Wallace, Alex. M. Weir(Thomson Reuters (United Kingdom))

Nature Reviews Drug Discovery

June 19, 2015

10.1038/nrd4609

Cited by 1,381

Abstract

Related Papers

Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success

Frank Lovering, Jack Bikker, Christine Humblet|Journal of Medicinal Chemistry|2009|4.3k

Can the pharmaceutical industry reduce attrition rates?

Ismail Kola, J. Richard Landis|Nature Reviews Drug Discovery|2004|4.1k

Drug-like properties and the causes of poor solubility and poor permeability

Christopher A. Lipinski|Journal of Pharmacological and Toxicological Methods|2000|3.7k

Clinical development success rates for investigational drugs

Michael Hay, David W. Thomas, John L. Craighead et al.|Nature Biotechnology|2014|2.5k

The influence of drug-like concepts on decision-making in medicinal chemistry

Paul D. Leeson, Brian Springthorpe|Nature Reviews Drug Discovery|2007|2.3k